Joshua Fitch, Senior Editor

A discussion of the intense 2023 RSV season, approved treatment tools, and an outlook for 2024.

Candice Jones, MD, shares what she wants to continue into the new year when it comes to pediatric health care.

Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses vaccine hesitancy and hopes to increase vaccination for preventable diseases in 2024.

In the third installment of RSV Roundtable, our panel discusses the impact nirsevimab has had this RSV season.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

William Gallentine, DO, explains the initial signs of pediatric seizures and epilepsy and how pediatricians can point them out, all while reassuring parents and determining proper care.

Birch triterpenes (FILSUVEZ; Chiesi Global Rare Diseases) is the first approved treatment for wounds associated with junctional epidermolysis bullosa (JEB), according to the developer.

In a recent phase 3 trial, omalizumab (Xolair; Genentech) led to children and adolescents being able to receive higher doses of common foods without allergic reactions.

A lead study investigator highlights epicutaneous immunotherapy using DBV 712 (Viaskin Peanut; DBV Technologies), its study details, and breaks down its usability, indications, and treatment potential.

Seborrheic dermatitis patients aged 9 years and older can now use roflumilast foam 0.3% following its approval by the FDA. 

In the second installment of RSV Roundtable, our panel explains how they are educating patients and parents when it comes to RSV, vaccines and preventive measures, and limited treatment availability.

Each year in the United States, there are approximately 700 to 800 cases of NB, of which 90% are diagnosed before the age of 5 years. More than half of these cases are considered high-risk.

The United States Preventive Services Task Force (USPSTF) is planning to recommend that comprehensive, intensive behavioral interventions be the primary effective intervention for weight loss in children and adolescents with high body mass indexes (BMI).

New data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition revealed emicizumab-kxwh (Hemlibra; Genentech) controlled bleeding in babies up to 12 months while demonstrating safety and tolerability.

No adverse events have been reported related to the recall of Vigabatrin for Oral Solution, USP 500 mg, which is indicated as an adjunctive therapy for refractory complex partial seizures in patients aged 2 years and older.

Lawrence Eichenfield, MD, discusses topical steroid, non-steroidal, and potentially new atopic dermatitis treatments for the pediatric population.

In a study that measured blood pressure (BP) in multiple stages of life until young adulthood, investigators concluded that lower BP levels early in life, maintained through young adulthood, could reduce the risk of cardiovascular disease (CVD).

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Sickle cell disease (SCD) patients aged 12 years and up can now be treated with exa-cel and lovo-cel, following simultaneous approval from the FDA on December 8, 2023.

Tina Tan, MD, FAAP, FIDSA, FPIDS, explains that the recent uptick in pediatric pneumonia cases across the country, which some have called "white lung syndrome," is nothing new, and there is no cause for panic.

The study authors wrote that future work could prioritize data from late summer and early fall seasons to better ascertain lead time values.

In this Contemporary Pediatrics interview, Lawrence Eichenfield, MD, explains additional challenges pediatric atopic dermatitis patients face during winter months and colder weather.

Investigators concluded that pharmacists at the pediatric HSSP performed clinical interventions beyond their daily clinical and operational activities, based on results from a study presented at the Health-System Pharmacists Midyear Clinical Meeting & Exhibition held in Anaheim, California, from December 3, 2023, to December 7, 2023.

In a poster abstract presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition held in Anaheim, California, stress ulcer prophylaxis (SUP) did not appear to provide benefit for prevention of gastrointestinal bleeding and did not increase SUP-associated adverse effects.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

According to the American Academy of Pediatrics (AAP), it is recommended that 45% to 65% of total daily calories come from carbohydrates, though very low-carbohydrate diets allow for 20 to 50 grams per day.

Lawrence Eichenfield, MD, reacts to the FDA's acceptance of a supplemental New Drug Application for roflumilast cream 0.15% to treat atopic dermatitis (AD) in patients aged 6 years and older.

The reaction, called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), can start as a rash but can progress quickly, potentially resulting in injury to internal organs, hospitalization, and death. 

The FDA has accepted a supplemental New Drug Application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in children aged 6 years and up.

Yamo Pharmaceuticals has initiated a phase 3 readiness program for L1-79, following the enrollment of its final patient in a phase 2 study evaluating the autism spectrum disorder (ASD) treatment for patients aged 2 to 21 years.